Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Precision Health Company Newtopia Secures Patent for Hyper-Personalized Disease Prevention Platform

share with twitter share with LinkedIn share with facebook
08/08/2017 | 09:31am EDT

NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Newtopia, a leading precision health company that utilizes genetic testing, behavioral science and smart technology to build highly personalized disease prevention programs for the enterprise, announced it has been granted a patent for its novel and hyper-personalized disease prevention platform. The patent represents seven years of effort to protect Newtopia’s innovative disease prevention solution.

Newtopia’s patent, U.S. Patent 9,554,754, is a system, method and computer program for weight, lifestyle and/or disease management integrating tailored nutrition, exercise and behavioral management information to create custom plans for users. The patent provides strong intellectual property protection of Newtopia’s proven approach to establishing meaningful one-to-one experiences by leveraging genetic and behavioral understanding to deliver engaging high touch, smart touch programs to reduce risk, prevent disease, and reduce healthcare costs.

“At Newtopia, we firmly believe that one size doesn’t fit all when it comes to effectively treating people at risk for developing preventable chronic diseases like Metabolic Syndrome,” said Newtopia founder and CEO Jeff Ruby.  “This patent recognizes our unique and highly targeted approach to precision health, which is unlike anything else in the market. And with it, we are successfully changing the common healthcare approach from what I refer to as sick care – care you receive when you’re already sick, to true healthcare – which is preventative care and measures taken to stave off diseases and maintain health.”

Newtopia is the only precision health program backed by scientific data with proven results that demonstrate higher engagement, outcomes and in-year savings. Aetna sponsored a 3-year Randomized Control Trial with Newtopia with initial 12-month outcomes published in the Journal of Occupational and Environmental Medicine, illustrating game-changing results. Newtopia helped participants reduce body weight, experience meaningful clinical improvements, and save $1,464 per employee per year. These savings are equivalent to a 2X return on investment in just the first year of the program.  The significant costs savings in the first year of participation provide an unequivocal return on investment long before the industry standard of three to five years.

About Newtopia
Newtopia is a precision health company leveraging genetic testing and the latest engagement science to inspire individuals to make healthy lifestyle decisions and reduce their risk of developing preventable chronic diseases. Newtopia's patented disease prevention platform combines personality-matched coaching with smart mobile technology to keep clients motivated and on track. Newtopia is partnering with insurers, employers and brands to offer disease prevention and management programs to risk-assessed individuals that deliver proven sustainable outcomes, quantifiable cost savings and a substantive ROI. Newtopia's programs and products are guideline and evidence-based and are available across the United States and Canada. 

Media Inquiries: 
Celena Fine

Primary Logo

© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
Latest news "Companies"
02:09pFIRSTENERGY : Media Advisory - Tropical Storm Isaias Update
02:01pCORELOGIC : Board of Directors Calls Special Meeting of Shareholders
01:56pAmazon and Mall Operator Look at Turning Sears, J.C. Penney Stores Into Fulfillment Centers -- Update
01:34pBMW : Solid results for Sykes, Laverty hugely unlucky on turbulent WorldSBK Sunday at Portimão.
01:21pAramco CEO sees oil demand picking up as lockdowns ease
01:21pSaudi Aramco's profit plunges, sees signs of oil market recovery
01:16pMYLAN N : ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL
Latest news "Companies"